October 23, 2014 7:12 AM ET

Pharmaceuticals

Company Overview of Cadence Pharmaceuticals Inc.

Company Overview

Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on acquiring, in-licensing, developing, and commercializing proprietary products principally for use in the hospital setting. The company holds the rights to OFIRMEV injection, a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever in adults and children. It distributes its products primarily through drug wholesalers to anesthesiologists and surgeons, as well as nurse anesthetists, emergency medicine physicians, intensivists, internists, hospitalists, obstetricians, and other ph...

12481 High Bluff Drive

Suite 200

San Diego, CA 92130

United States

Founded in 2004

210 Employees

Phone:

858-436-1400

Fax:

858-436-1401

Key Executives for Cadence Pharmaceuticals Inc.

Co-Founder
Age: 59
Chief Financial Officer
Age: 62
Senior Vice President
Age: 58
Chief Commercial Officer and Senior Vice President
Age: 44
Director of Investor Relations
Compensation as of Fiscal Year 2014.

Cadence Pharmaceuticals Inc. Key Developments

Cadence Pharmaceuticals, Inc. Enters into Settlement Agreement with Fresenius Kabi USA, LLC

Cadence Pharmaceuticals Inc. has entered into settlement and license agreements with Fresenius Kabi USA, LLC, resolving pending patent litigation involving OFIRMEV(R) (acetaminophen) injection. The companies are not disclosing specific terms of the settlement and license agreements. Cadence had filed suit against Fresenius Kabi in January 2013. Other details of the settlement are confidential, and the settlement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice. The settlement and license agreements will become effective upon the entry by the U.S. District Court of an order dismissing with prejudice the litigation with respect to Fresenius Kabi.

Cadence Pharmaceuticals, Inc. Enters into Settlement and License Agreements with Fresenius Kabi USA, LLC

Cadence Pharmaceuticals Inc. has entered into settlement and license agreements with Fresenius Kabi USA, LLC, resolving pending patent litigation involving OFIRMEV(R) (acetaminophen) injection. The companies are not disclosing specific terms of the settlement and license agreements, except that Cadence has granted Fresenius Kabi a non-exclusive right to market an intravenous acetaminophen product in the U.S. under Fresenius Kabi's 505(b)(2) New Drug Application on December 6, 2020, or earlier under certain circumstances. Cadence had filed suit against Fresenius Kabi in January 2013. The settlement and license agreements will become effective upon the entry by the U.S. District Court of an order dismissing with prejudice the litigation with respect to Fresenius Kabi.

Cadence Pharmaceuticals Inc.(NasdaqGM:CADX) dropped from NASDAQ Biotechnology Index

Cadence Pharmaceuticals Inc. will be removed from the NASDAQ Biotechnology Index.

Similar Private Companies By Industry

Company Name Region
BSP Pharma, Inc. United States
Carnrick Laboratories Inc. United States
IVAX Laboratories, Inc. United States
Medelis, Inc. United States
Cognosci Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
February 11, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cadence Pharmaceuticals Inc., please visit www.cadencepharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.